Analysts’ Recent Ratings Updates for Merit Medical Systems (MMSI)

Several brokerages have updated their recommendations and price targets on shares of Merit Medical Systems (NASDAQ: MMSI) in the last few weeks:

• 5/8/2026 – Merit Medical Systems was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/1/2026 – Merit Medical Systems was given a new $83.00 price target by Robert W. Baird.
• 5/1/2026 – Merit Medical Systems had its price target lowered by Canaccord Genuity Group Inc. from $90.00 to $85.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Merit Medical Systems had its price target lowered by JPMorgan Chase & Co. from $95.00 to $77.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Merit Medical Systems had its price target lowered by Wells Fargo & Company from $78.00 to $74.00. They now have an “equal weight” rating on the stock.
• 5/1/2026 – Merit Medical Systems had its price target lowered by Needham & Company LLC from $101.00 to $90.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Merit Medical Systems was given a new $107.00 price target by Compass Point.
• 4/20/2026 – Merit Medical Systems had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/20/2026 – Merit Medical Systems had its price target lowered by Barrington Research from $109.00 to $107.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Merit Medical Systems had its price target lowered by Piper Sandler from $106.00 to $96.00. They now have an “overweight” rating on the stock.
• 4/7/2026 – Merit Medical Systems had its price target lowered by Canaccord Genuity Group Inc. from $99.00 to $90.00. They now have a “buy” rating on the stock.
• 4/5/2026 – Merit Medical Systems was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/1/2026 – Merit Medical Systems had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $101.00 price target on the stock.
• 3/28/2026 – Merit Medical Systems was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 3/27/2026 – Merit Medical Systems had its “hold (c)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Merit Medical Systems

In other news, insider Brian G. Lloyd bought 2,000 shares of the stock in a transaction on Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. This trade represents a 39.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is currently owned by corporate insiders.

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.